We tested several PI3K, AKT and MTOR inhibitors, most of which are FDA-approved or in clinical trials for the treatment of hematological malignancies or solid tumors, in the human B-ALL cell lines RCH-ACV, 697, REH and SEM. This evidence concerns the gene AKT1 and hematologic disorder.